Raamdeo Agrawal recalls Rakesh Jhunjhunwala’s exceptional ability to spot undervalued stocks and build long-term wealth, highlighting his f...

Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

India's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correct...

Happy Wednesday! Meta just handed WhatsApp’s steering wheel to Cred’s Kunal Shah, betting he can turn India’s favourite chat app into a pay...

India's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...

Vedanta Aluminium is likely to be upgraded to the large-cap category in AMFI’s H2 CY26 semi-annual reshuffle, while Vedanta Power, Oil & Ga...

Smallcap funds have emerged as the best-performing equity mutual fund category over the last three months, delivering an average return of ...

Outgoing Director of National Intelligence Tulsi Gabbard has leveled serious accusations against Anthony Fauci, alleging he funneled US tax...

Nikhil Kamath water business idea: India's rapid growth in water-intensive sectors like agriculture, nuclear energy, pharmaceuticals, and d...

Happy Friday! Personal care giant L’Oreal has acquired a majority stake in Innovist in India’s biggest D2C deal. This and more in today’s E...

The reason NBFC stocks reacted quickly to the easing of the US-Iran war risk is not difficult to understand. For a lender, macro relief tra...

From a macro perspective, it is clearly a good time to be bullish. But as valuations remain high in parts of the market despite the recent ...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Aman Chowhan of Abakkus Asset Manager highlights crude oil as the dominant macro risk, potentially impacting corporate earnings by 100-200 ...

Indian equities are nearing a crucial turning point, with market veteran Gautam Shah suggesting a shift in focus beyond benchmark indices. ...

With an eye on India's blossoming market, Novartis is set to launch pioneering therapies, including radioligand and gene therapies. The com...

Zahabiya Khorakiwala is leading Wockhardt's US business and the launch of its new antibiotic, Zaynich. This drug targets resistant bacteria...